The recent torrent of innovation in cancer screening technologies promise significant improvements in early detection and diagnosis. While many of these novel or non-standard techniques and approaches have the potential to improve patient experiences or screen for cancers that were previously unable to be screened for, some of the most promising are still being evaluated. So what is the right way to think about integrating these novel technologies into preventive care?

Advances in genome sequencing and machine learning have facilitated the development of blood-based multi-cancer early detection tests intended to complement single-cancer screening. Hear how MCED tests can interrogate circulating cell-free DNA to detect a shared cancer signal across multiple tumour types

We know that improving access to evidence-based screening, early diagnosis and timely treatment is essential for avoiding mortality and morbidity for patients, wasting resources and increasing costs of late-stage care. So, why does equitable access to screening, earlier diagnosis and treatment remain slow? Our panel discusses improving access to screening, diagnosis and treatment emphasising the role of innovation and best practices